Myriad Genetics
MYGN
MYGN
201 hedge funds and large institutions have $2.3B invested in Myriad Genetics in 2021 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 71 increasing their positions, 61 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
201
Holders Change
+4
Holders Change %
+2.03%
% of All Funds
3.51%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
27
Increased
71
Reduced
61
Closed
22
Calls
$4.34M
Puts
$2.98M
Net Calls
+$1.36M
Net Calls Change
-$1.7M
Top Buyers
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
$34.1M |
| 2 |
Goldman Sachs
New York
|
$67.7M |
| 3 |
JPMorgan Chase & Co
New York
|
$24.3M |
| 4 |
BlackRock
New York
|
$416M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
$94.5M |
Top Sellers
| 1 |
EARNEST Partners
Atlanta,
Georgia
|
$189M |
| 2 |
D.E. Shaw & Co
New York
|
$68.6M |
| 3 |
Two Sigma Investments
New York
|
$2.64M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
$76M |
| 5 |
Invesco
Atlanta,
Georgia
|
$23.4M |
